MyKronoz Introduces ZePods Fashionable and Colorful True Wireless Earbuds, Together with a New Line of Affordable Smartwatches
26.2.2019 14:38:00 EET | Business Wire | Press release
Swiss wearable brand MyKronoz today announced ZePods, its first collection of true wireless earphones, unveiled at Mobile World Congress Barcelona 2019. Offering an impressive sound quality, up to 15 hours of playtime, stylish design with 6 vibrant colors and matching USB-C charging case, intuitive touch control to manage music, calls and voice commands thanks to its Bluetooth 5.0 technology - MyKronoz’s first true wireless earbuds will come in two versions with distinctive design and features:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190226005577/en/
ZePods - Wireless TWS earbuds (Photo: MyKronoz)
- ZePods, with a USB-C charging case boasting the familiar look of a sleek lighter. Available in April 2019 for a MSRP of 79,90€/$ only.
- ZePods+, with a Qi-certified wireless charging case whose shape has been greatly inspired by Swiss traditional pocket-watch. Available H2 2019 for a MSRP of 99,90€/$.
"Building on our Swiss DNA for design and our strong background in wearable technology, we believe that MyKronoz has a tremendous opportunity to seize in the flourishing market of wireless earbuds. The launch of ZePods appears as a natural and strategic evolution for our company to leverage expertise in developing affordable consumer-driven products and diversify to offer a full ecosystem." said Boris Brault, MyKronoz Founder and CEO.
In addition to ZePods, MyKronoz goes back to basics of affordable fashion wearables with a complete new line starting at 29.90 €/$, featuring activity tracker, smartwatches, sport smartwatches and hybrids to cater a large and diversified audience. Among the new collection, 4 products highlights:
- ZeTrack - a slim and full-featured HR activity tracker with color touchscreen. MSRP: 29.90€/$ - Launch date: end of March 2019.
- ZeNeo - a real powerful smartwatch with mic & speaker that looks like a sleek activity tracker. MSRP: 59.90€/$ - Launch date: end of April 2019.
- ZeRound3 Lite - the go-to smartwatch designed for your active lifestyle. MSRP: 79.90€/$ - Launch date: end of April 2019.
- ZeRound3 - the genuinely stylish connected smartwatch with AMOLED display. MSRP: 99.90€/$ - Launch date: end of March 2019.
The rest of the range includes ZeSport2, a multi-sport GPS smartwatch, already available at a MSRP of 149.90€/$. MyKronoz will continue to innovate in H2 2019 with ZePop - the hybrid smartwatch that blends fashion and tech. MSRP: 129,90€/$ as well as ZeTime2 - a stainless steel hybrid smartwatch with microphone, AMOLED display and real mechanical hands. MSRP: 199,90€/$.
ZePods, as well as the MyKronoz full new wearable collection will be on display and available for demos on the MWC 2019 show foor at the MyKronoz booth in the Congress Square (Booth #CS118) February 25-28th, 2019.
ABOUT MYKRONOZ:
MyKronoz is part of BOW Group, a global player in lifestyle consumer products, operating worldwide in the design and wearables markets with its 2 brands: MyKronoz and LEXON.
Since July 2015, BOW has opened up its capital to Next Stage AM, then, in 2017 to PM Equity Partner - the corporate venture fund of Philip Morris International. MyKronoz ZeTime has convinced over 40,000 backers in more than 100 countries and became the world's highest funded hybrid smartwatch with more than $8 million raised, as well as the largest crowdfunding campaign ever from a European company and the most backed product of 2017 on Kickstarter.
BOW Group has now more than 100 talents spread across four office locations: Paris, Geneva, Miami and Shenzhen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190226005577/en/
Contact information
International media:
Annabel
Corlay
press@mykronoz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
